The role of aldosterone receptor blocker therapy in hypertension and heart failure
| Autor: | Rosanna Trane, Antonietta Schipani, Cosimo Stefanio, F. Zaca, Giuseppina Santese, Maria Boiani, Gianluca Belletti |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Arterial hypertension
Drug medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism media_common.quotation_subject Heart failure medicine.disease Aldosterone receptor blockers Mineralocorticoid receptor Refractory Tolerability Physiology (medical) Internal medicine medicine Cardiology Canrenone Metabolic syndrome Cardiology and Cardiovascular Medicine business medicine.drug media_common Hormone |
| Zdroj: | IJC Metabolic & Endocrine. 8:34-37 |
| ISSN: | 2214-7624 |
| DOI: | 10.1016/j.ijcme.2014.10.010 |
| Popis: | The aldosterone receptor blocker therapy as an “add-on” to hypotensive therapy is an excellent therapeutic strategy that has proved to be particularly effective in treating refractory hypertension, hypertension with organ damage and overweight hypertensive patients. Aldosterone receptor blockers are extremely useful in inhibiting hormonal activation linked with heart failure: they have cardioprotective effects not only during full-blown heart failure, but also in its early stages, and this effect can be observed even more frequently in heart failures with metabolic syndrome. The use of molecules such as canrenone with a favorable tolerability profile ensures a better tolerability ratio by providing benefits linked to fewer drug interactions, lower incidence of side effects and improved therapy adherence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|